A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found.
The drug, Tezepelumab (also known as Tezspir and made by AstraZeneca), works by binding to and blocking a protein that drives airway inflammation.